Founded in 1998 in France, Provepharm is a leading biopharmaceutical company that uses its expertise in fine chemistry for the revitalization of known molecules. The company develops the only injectable methylene blue product approved by the US Food & Drug Administration (FDA) and has received the orphan drug designation for the treatment of methemoglobinemia in the US. Provepharm’s strategy is currently focused on developing Proveblue®/ Provayblue™/ BLUDIGO™ for new indications, applying its expertise for the revitalization of other molecules
in promising niche markets and strengthening its international reach.